Biofrontera receives FDA approval to increase Ameluz topical gel dosage for actinic keratosis treatment on face and scalp.
Biofrontera Inc. has received FDA approval to increase the maximum dosage of its Ameluz topical gel from one to three tubes per treatment for actinic keratosis (AK) on the face and scalp. This decision, based on two Phase I safety studies involving 116 patients, allows for larger area treatment using Ameluz-PDT with specific lamps. The company will now engage with Medicare and commercial payers regarding reimbursement for this update.
October 07, 2024
5 Articles